GKOS
GLAUKOS Corp
NYSE · Healthcare · Medical - Devices · US
$163.81
+1.48%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$162.43
From 52W high−13.58%
Volume1.46M
Market cap$9.66B
P/E (TTM)—
P/S (TTM)15.8x
Div yield—
Key dataSep 18, 2026
Open
$162.43
From 52W high
−13.58%
Volume
1.46M
Market cap
$9.66B
ValuationView details →
P/E (Fwd)
1068.3x
EV/EBITDA
−66.6x
P/E (TTM)
—
RSI (14)
35.2
MomentumView details →
1D Return
+1.48%
YTD Return
+41.56%
SummaryUpdated Jun 1, 2026
Glaukos Corporation (NASDAQ:GKOS) is a specialized ophthalmic medical technology and pharmaceutical company founded in 1998 and headquartered in San Clemente, California. The company went public in June 2015 and has established itself as a pioneer in minimally invasive glaucoma surgery (MIGS) and innovative ocular therapeutics. Glaukos focuses on developing and commercializing novel therapies for treating glaucoma, corneal disorders, and retinal diseases, with a particular emphasis on what it calls "interventional glaucoma" - a proactive approach to treating eye pressure and preventing vision loss before significant damage occurs.
Similar companies
Latest newsMore news →
Glaukos Corporation reported its second quarter 2026 financial results, posting a net loss of $0.14 per share, which beat the Zacks Consensus Estimate of a loss of $0.28 per share and improved from a loss of $0.24 per share in the same quarter a year ago.53d agoGlaukos completed patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt in adult patients with primary open-angle glaucoma.55d ago